Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Invested Capital (2018 - 2025)

Historic Invested Capital for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $3.7 billion.

  • Takeda Pharmaceutical's Invested Capital fell 9298.85% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.0 billion, marking a year-over-year decrease of 7160.24%. This contributed to the annual value of $75.2 billion for FY2025, which is 1053.28% down from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Invested Capital is $3.7 billion, which was down 9298.85% from $52.1 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Invested Capital ranged from a high of $92.7 billion in Q1 2021 and a low of $3.7 billion during Q4 2025
  • Over the past 5 years, Takeda Pharmaceutical's median Invested Capital value was $52.7 billion (recorded in 2022), while the average stood at $55.0 billion.
  • Within the past 5 years, the most significant YoY rise in Takeda Pharmaceutical's Invested Capital was 129239.18% (2025), while the steepest drop was 9298.85% (2025).
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Invested Capital stood at $51.0 billion in 2021, then fell by 7.23% to $47.3 billion in 2022, then grew by 4.23% to $49.3 billion in 2023, then grew by 6.91% to $52.7 billion in 2024, then tumbled by 92.99% to $3.7 billion in 2025.
  • Its Invested Capital stands at $3.7 billion for Q4 2025, versus $52.1 billion for Q3 2025 and $51.2 billion for Q2 2025.